Allelix Neuroscience Inc.

Memory Pharmaceuticals Corporation

Michael De Vivo

Richard A Schumacher

Ashok Tehim

Stanley Charles Bell

Allen T Hopper

Laurence A Borden

Ruiping Liu

William F Brubaker

Vivian R Albert

Axel Unterbeck

Vassil Ilya Ognyanov

Allen Hopper

Midori Yokoyama

Eric A Meade

Methvin Isaac

Hans-J&uuml;rgen Ernst Hess

Daguang Wang

Anne O'Brien

Hans-Jürgen Ernst Hess

The present invention relates e.g., to QM-7 or QT-6 cells comprising a heterologous mutant nicotinic &#x3b1;7 acetylcholine receptor and/or a nucleic acid encoding it, or a fragment or variant thereof. In a preferred embodiment, the mutant nicotinic &#x3b1;7 acetylcholine receptor subunit has a mutation in the M2 domain. QM-7 and QT-6 cells of the invention are useful for, e.g., assays such as high throughput assays that measure the influx of cations, such as Caions, into a cell. Such assays can be used, e.g., to identify agents that modulate the expression and/or activity of a mutant cell-surface-expressed channel receptor (e.g., the nicotinic &#x3b1;7 receptor), and which thus modulate, e.g., among other functions, processes involved in the central nervous system, such as learning and memory.

QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells

PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R, R, Rand Rare as defined herein.

Phosphodiesterase 4 inhibitors

Described herein are compounds having the general formula: ##STR1## wherein: Ar.sup.1 and Ar.sup.2 are independently selected aryl groups, optionally substituted with substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, alkanoyl, aralkyl, aralkyloxy, halo, NO.sub.2, Ph, CF.sub.3, CN, OH, methylenedioxy, ethylenedioxy, SO.sub.2 NRR', NRR', CO.sub.2 R (where R and R' are independently selected from the group consisting of H and alkyl) and a second aryl group, which may be substituted as above; wherein any cycloalkyl or aryl substituent is linked to Ar.sup.1 or Ar.sup.2 by a bridging element which may be a single bond, a vinylene group, an ethynylene group, a Z group, a --Z--(CH.sub.2).sub.n -- group, a --(CH.sub.2).sub.n --Z-- group, or a --Z--(CH.sub.2).sub.n --Z-- group, where Z represents an O atom, a S atom, an NH group or an N-alkyl group, and n is an integer from 1 to 4; wherein Ar.sup.1 and Ar.sup.2 may be attached to the central atom to which they are connected by a single bond, an alkylene, alkenylene or alkynylene group; wherein Ar.sup.1 and Ar.sup.2 may be attached to the central atom to which they are connected by a single bond, an alkylene, alkenylene or alkynylene group; R.sup.3 is selected from the group consisting of H and aryl, which may be substituted as for Ar.sup.1 ; R.sup.4 and R.sup.5 are independently selected from the group consisting of H, alkyl, alkanoyl, benzoyl and benzyl.

Amino acid derivatives

Described herein are compounds which have the general formula: ##STR1## or a prodrug or pharmaceutically acceptable salt, solvate or hydrate thereof wherein:

Tricylic amino-acid derivatives

The present invention relates to materials and methods for the identification of agents that regulate glycine transport in or out of cells, particularly in or out of neuronal and neuronal-associated cells. Such materials include non-mammalian cells having transfected therein a glycine transporter. The methods relate to the manipulation of such cells such that agents are identified that cause intake or outflow of glycine with respect to a given glycine transporter.

Glycine transporter-transfected avian cells and uses thereof

Glycine transporter-transfected cells and uses thereof

Growing community of inventors

New York, NY, United States of America

Michael De Vivo